Capsule Summary Slidesets


Share

Program Content

Activities

  • AZD0486 for RR FL
    AZD0486, a CD19 x CD3 Bispecific Antibody, for Relapsed/Refractory Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2024

    Expires: December 08, 2025

  • MITHIC FL1 Mosunetuzumab
    MITHIC-FL1: Phase II Study of Single-Agent Mosunetuzumab in Patients With Newly Diagnosed Follicular Lymphoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2024

    Expires: December 08, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation